FORM 7  
  
MONTHLY PROGRESS REPORT

May 2018

Name of Listed Issuer: Veritas Pharma Inc. (the “Company”).

Trading Symbol: VRT

Number of Outstanding Listed Securities: 69,296,800 common shares

Date: June 11, 2018

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**On May 7, 2018, the Company is pleased to announced the establishment of a new subsidiary Veritas Pharma Puerto Rico LLC (“Veritas PR”) in the US territory. With the management and regulatory guidance of Essentium Group LLC, Veritas PR establishes a foothold for the scientific investigation, product development and commercialization of cannabis-based therapies in Puerto Rico and throughout Latin America.**

**Veritas PR will commence the upcoming human trials of Cannevert Therapeutics Ltd (“CTL”) lead cannabis strain, CTL-X. The trials are being conducted by Fundacion de Investigacion Clinical research facilities in San Juan, Puerto Rico.**

**On May 10, 2018, the company provided the following statement to the recommendation issued by Members of the Standing Senate Committee on Aboriginal Peoples calling for a one-year deferment to allow further consultation with Indigenous groups on May 1, 2018.**

**Members of the Standing Senate Committee on Aboriginal Peoples in the Canadian Senate are recommending the Liberal government hold back on legalizing cannabis for up to a year in order to address its potential for harmful effects in Indigenous communities. Scott Alexander, the Medical Director at Veritas Pharma stated the following:**

**“"We believe that due diligence should be done in structuring Bill C-45 to ensure that all Canadians concerns are addressed. Veritas is solely focused on the medicinal properties of cannabis and our work in Canada is completed in a Health Canada approved facility. We will not be affected by any delays in the passing of Bill C-45 in our continued pursuit of scientific research into the use of cannabis for medical purposes as we seek to maximize its therapeutic effects and minimize the adverse effects that some patients experience."**

**On May 15, 2018, the Company announced with the dealer license being granted which was previously announced on December 28, 2017, the Company has now engaged a branding firm in the development of label and package design in compliance with Health Canada regulations. Veritas is applying to amend Cannevert’s Dealer License such that the Company can package Cannevert products including CTL-X for sale to licensed producers in Canada and for the export marketing.**

**CBD Strategy Group, a cannabis brand and marketing firm, has been retained to help develop brand strategy and guidelines around compliant packaging and labelling for both cannabis import and export.**

1. Provide a general overview and discussion of the activities of management.

**Please refer to Question 1**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Please refer to Question 1.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None.**

1. Describe the acquisition of new customers or loss of customers.

**None.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None**

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None.**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**None.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None.**

1. Provide details of any securities issued and options or warrants granted.

**None.**

1. Provide details of any loans to or by Related Persons.

**None.**

1. Provide details of any changes in directors, officers or committee members.

**None**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**None.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 11, 2018

David Alexander  
Name of Director or Senior Officer

“David Alexander”  
Signature

Chief Financial Officer   
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer  Veritas Pharma Inc. | For Month End  May 2018 | Date of Report  YY/MM/D  2018/06/11 |
| Issuer Address  Suite 310 – 221 West Esplanade, North Vancouver, BC V7M 3J3 | | |
| City/Province/Postal Code  Vancouver, B.C., V6T 1Z3 | Issuer Fax No.  (778)262-0120 | Issuer Telephone No.  (778)968-6260 |
| Contact Name  David Alexander | Contact Position  CFO | Contact Telephone No.  778-772-8184 |
| Contact Email Address  ir@veritaspharmainc.com | Web Site Address  www.veritaspharmainc.com | |